INTERVENTION / TREATMENT PEARLS 2012

Intervention/ Treatment	Expected decrease in A1C with monotherapy (%)	Primary Action	When to Choose/Use	Cost
Lifestyle changes in diet/physical activity to promote weight loss	1.0-2.0	Broad benefits to health	Improvement in lifestyle possible Person can begin immediately	Free-\$
Metformin	1.0-2.0	Lowers fasting plasma glucose	All patients unless contraindicated or not tolerated	\$
Sulfonylurea	1.0-2.0	Lowers fasting plasma glucose	Second agent for most patients Hypoglycemia risk high	\$
Alpha Glucosidase Inhibitors	0.5-1.0	Lowers post-prandial glucose	Slow carbohydrate Taken orally	\$-\$\$
Meglitinides	0.5-1.5	Lowers post-prandial glucose	Sulfa allergy Lower risk hypoglycemia	\$-\$\$
Pioglitazone	0.6-1.0	Lowers post-prandial glucose	Insulin resistance high High triglycerides and low HDL if using maximum dose	\$\$-\$\$\$
GLP-1 Agonist	0.8-1.5	Lowers post-prandial and fasting glucose	Weight loss desired No hypoglycemia	\$\$\$
DPP-IV Inhibitors	0.6-0.8	Lowers post- prandial glucose	Weight neutralTaken orallyMay use in renal insufficiency	\$\$\$
Pramlintide	0.4-0.6	Lowers post-prandial glucose	Wide fluctuating post-prandial glucose	\$\$\$

Guiding Principles:

- The tool "Type 2 Diabetes: Ambulatory Glycemic Control Pathway" provides a framework for approaching the management of type 2 diabetes
- Use the tool "Diabetes Mellitus Medications 2012" for specific drug-related information
- General Glycemic control goals: A1C < 7.0% (always individualize); Fasting Plasma Glucose (FPG) 70-130 mg/dL; two-hour post-prandial < 180 mg/dL
- Selection of medications should be based on patterns of hyperglycemia (e.g., elevated FPG and/or elevated post-prandial)
- Medication should be titrated to maximal effective doses